Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 3/2013

01-06-2013 | Research Article

Quantitative synthesis of the association between the cytochrome P450 1A1 Ile462Val polymorphism and prostate cancer risk

Authors: Guangye Han, Yanjuan Ma, Pei Liu, Xiaoxia Wei, Xinjun Zhang, Feng Zhu

Published in: Tumor Biology | Issue 3/2013

Login to get access

Abstract

The association between the cytochrome P450 1A1 (CYP1A1) Ile462Val polymorphism and prostate cancer risk remains inconclusive owing to the conflicting findings from previous studies. To get a more precise estimate of the possible association, we performed the present meta-analysis. We searched the PUBMED, EMBASE, and Wanfang databases for the studies which met the inclusion criteria. The pooled odds ratio (OR) with corresponding 95 % confidence interval (95 % CI) was used to estimate the association between CYP1A1 Ile462Val polymorphism and prostate cancer risk. A total of 13 studies with 2,350 cases and 2,992 controls were included in the meta-analysis. The results indicated that there was an obvious association between CYP1A1 Ile462Val polymorphism and increased risk of prostate cancer (for Val versus Ile: OR = 1.27, 95 % CI 1.13–1.43, P < 0.001; for ValVal versus IleIle: OR = 1.51, 95 % CI 1.14–2.01, P = 0.004; for ValVal + ValIle versus IleIle: OR = 1.31, 95 % CI 1.14–1.51, P < 0.001; for ValVal versus IleIle + ValIle: OR = 1.38, 95 % CI 1.05–1.81, P = 0.020). Subgroup analyses by ethnicity suggested that CYP1A1 Ile462Val polymorphism was associated with prostate cancer risk in Asians but not in Caucasians. This meta-analysis suggests that there is an association between CYP1A1 Ile462Val polymorphism and increased risk of prostate cancer. More studies with large sample are needed to further assess the association in Caucasians.
Literature
1.
2.
3.
4.
Risbridger GP, Davis ID, Birrell SN, Tilley WD. Breast and prostate cancer: more similar than different. Nat Rev Cancer. 2010;10:205–12.PubMedCrossRef
5.
Nebert DW, Jones JE. Regulation of the mammalian cytochrome P1-450 (CYP1A1) gene. Int J Biochem. 1989;21:243–52.PubMedCrossRef
6.
Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. The CYP1A1 gene and cancer susceptibility. Crit Rev Oncol Hematol. 1993;14:77–87.PubMedCrossRef
7.
Lourenco GJ, Silva EF, Rinck-Junior JA, Chone CT, Lima CS. CYP1A1, GSTM1 and GSTT1 polymorphisms, tobacco and alcohol status and risk of head and neck squamous cell carcinoma. Tumour Biol. 2011;32:1209–15.PubMedCrossRef
8.
Nebert DW, Petersen DD, Puga A. Human ah locus polymorphism and cancer: inducibility of CYP1A1 and other genes by combustion products and dioxin. Pharmacogenetics. 1991;1:68–78.PubMedCrossRef
9.
Androutsopoulos VP, Tsatsakis AM, Spandidos DA. Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer. 2009;9:187.PubMedCrossRef
10.
Yang S, Jia C, Zhu H, Han S. CYP1A1 Ile462Val polymorphism and cervical cancer: evidence from a meta-analysis. Tumour Biol. 2012;33:2265–72.PubMedCrossRef
11.
Murata M, Watanabe M, Yamanaka M, Kubota Y, Ito H, Nagao M, et al. Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett. 2001;165:171–7.PubMedCrossRef
12.
Beer TM, Evans AJ, Hough KM, Lowe BA, McWilliams JE, Henner WD. Polymorphisms of GSTP1 and related genes and prostate cancer risk. Prostate Cancer Prostatic Dis. 2002;5:22–7.PubMedCrossRef
13.
Suzuki K, Matsui H, Nakazato H, Koike H, Okugi H, Hasumi M, et al. Association of the genetic polymorphism in cytochrome P450 (CYP) 1A1 with risk of familial prostate cancer in a Japanese population: a case-control study. Cancer Lett. 2003;195:177–83.PubMedCrossRef
14.
Aktas D, Hascicek M, Sozen S, Ozen H, Tuncbilek E. CYP1A1 and GSTM1 polymorphic genotypes in patients with prostate cancer in a Turkish population. Cancer Genet Cytogenet. 2004;154:81–5.PubMedCrossRef
15.
Guan TY, Li M, Na YQ. [Polymorphism of metabolic gene and genetic susceptibility to prostate cancer]. Zhonghua Wai Ke Za Zhi. 2005;43:1467–70.PubMed
16.
Nock NL, Liu X, Cicek MS, Li L, Macarie F, Rybicki BA, et al. Polymorphisms in polycyclic aromatic hydrocarbon metabolism and conjugation genes, interactions with smoking and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15:756–61.PubMedCrossRef
17.
Yang J, Qian LX, Wu HF, Xu ZQ, Sui YG, Wang XR, et al. Genetic polymorphisms in the cytochrome P450 1A1 and 2E1 genes, smoking, drinking and prostate cancer susceptibility: a case-control study in a Han nationality population in Southern China. Int J Urol. 2006;13:773–80.PubMedCrossRef
18.
Berndt SI, Chatterjee N, Huang WY, Chanock SJ, Welch R, Crawford ED, et al. Variant in sex hormone-binding globulin gene and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:165–8.PubMedCrossRef
19.
Kumar V, Yadav CS, Singh S, Goel S, Ahmed RS, Gupta S, et al. CYP 1A1 polymorphism and organochlorine pesticides levels in the etiology of prostate cancer. Chemosphere. 2010;81:464–8.PubMedCrossRef
20.
Rodrigues IS, Kuasne H, Losi-Guembarovski R, Fuganti PE, Gregorio EP, Kishima MO, et al. Evaluation of the influence of polymorphic variants CYP1A1 2B, CYP1B1 2, CYP3A4 1B, GSTM1 0, and GSTT1 0 in prostate cancer. Urol Oncol. 2011;29:654–63.PubMedCrossRef
21.
Higgins J, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine. 2002;21:1539–58.PubMedCrossRef
22.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
23.
24.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef
25.
Caceres DD, Iturrieta J, Acevedo C, Huidobro C, Varela N, Quinones L. Relationship among metabolizing genes, smoking and alcohol used as modifier factors on prostate cancer risk: exploring some gene-gene and gene-environment interactions. Eur J Epidemiol. 2005;20:79–88.PubMedCrossRef
26.
Quinones LA, Irarrazabal CE, Rojas CR, Orellana CE, Acevedo C, Huidobro C, et al. Joint effect among p53, CYP1A1, GSTM1 polymorphism combinations and smoking on prostate cancer risk: an exploratory genotype-environment interaction study. Asian J Androl. 2006;8:349–55.PubMedCrossRef
27.
Silig Y, Pinarbasi H, Gunes S, Ayan S, Bagci H, Cetinkaya O. Polymorphisms of CYP1A1, GSTM1, GSTT1, and prostate cancer risk in Turkish population. Cancer Invest. 2006;24:41–5.PubMedCrossRef
28.
Beuten J, Gelfond JA, Franke JL, Weldon KS, Crandall AC, Johnson-Pais TL, et al. Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:1869–80.PubMedCrossRef
29.
Koutros S, Berndt SI, Sinha R, Ma X, Chatterjee N, Alavanja MC, et al. Xenobiotic metabolizing gene variants, dietary heterocyclic amine intake, and risk of prostate cancer. Cancer Res. 2009;69:1877–84.PubMedCrossRef
30.
Souiden Y, Mahdouani M, Chaieb K, Bakhrouf A, Mahdouani K. Lack of association of CYP1A1 polymorphism with prostate cancer susceptibility of Tunisian men. Genet Test Mol Biomarkers. 2012;16:661–6.PubMedCrossRef
31.
Holt SK, Kwon EM, Fu R, Kolb S, Feng Z, Ostrander EA, et al. Association of variants in estrogen-related pathway genes with prostate cancer risk. Prostate. 2013;73:1–10.PubMedCrossRef
32.
Chang BL, Zheng SL, Isaacs SD, Turner A, Hawkins GA, Wiley KE, et al. Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk. Int J Cancer. 2003;106:375–8.PubMedCrossRef
33.
Gao JP, Huang YD, Yang GZ, Yang YQ. Relationship between genetic polymorphisms of metabolizing enzymes and prostate cancer. National Journal OF Andrology. 2003;9:32–5.PubMed
34.
Li M, Guan TY, Li Y, Na YQ. Polymorphisms of GSTM1 and CYP1A1 genes and their genetic susceptibility to prostate cancer in Chinese men. Chin Med J (Engl). 2008;121:305–8.
35.
Otsuka T, Iguchi K, Fukami K, Ishii K, Usui S, Sugimura Y, et al. Androgen receptor W741C and T877A mutations in AIDL cells, an androgen-independent subline of prostate cancer LNCaP cells. Tumour Biol. 2011;32:1097–102.PubMedCrossRef
36.
Ma Y, Liang D, Liu J, Axcrona K, Kvalheim G, Giercksky KE, et al. Synergistic effect of SCF and G-CSF on stem-like properties in prostate cancer cell lines. Tumour Biol. 2012;33:967–78.PubMedCrossRef
37.
Pienta KJ, Smith DC. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin. 2005;55:300–18. quiz 323-305.PubMedCrossRef
38.
Anwar-Mohamed A, Elbekai RH, El-Kadi AO. Regulation of CYP1A1 by heavy metals and consequences for drug metabolism. Expert Opin Drug Metab Toxicol. 2009;5:501–21.PubMedCrossRef
39.
Huang Q, Deshmukh RS, Ericksen SS, Tu Y, Szklarz GD. Preferred binding orientations of phenacetin in CYP1A1 and CYP1A2 are associated with isoform-selective metabolism. Drug Metab Dispos. 2012;40:2324–31.PubMedCrossRef
Metadata
Title
Quantitative synthesis of the association between the cytochrome P450 1A1 Ile462Val polymorphism and prostate cancer risk
Authors
Guangye Han
Yanjuan Ma
Pei Liu
Xiaoxia Wei
Xinjun Zhang
Feng Zhu
Publication date
01-06-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0676-4

Other articles of this Issue 3/2013

Tumor Biology 3/2013 Go to the issue

Research Article

Association between the C3435T polymorphism of ABCB1/MDR1 gene (rs1045642) and colorectal cancer susceptibility

Research Article

Association between XRCC3 Thr241Met polymorphism and colorectal cancer risk

Research Article

RETRACTED ARTICLE: Comparison of hepatocellular carcinoma (HCC), cholangiocarcinoma (CC), and combined HCC-CC (CHC) with each other based on microarray dataset

Research Article

Lactate dehydrogenase A is overexpressed in pancreatic cancer and promotes the growth of pancreatic cancer cells

Research Article

Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profilin 1

Research Article

The transcription factor DEC1 (BHLHE40/STRA13/SHARP-2) is negatively associated with TNM stage in non-small-cell lung cancer and inhibits the proliferation through cyclin D1 in A549 and BE1 cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits